Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia TranscriptSeeking Alpha • 11/15/26
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBusiness Wire • 11/14/26
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH ExpertsBusiness Wire • 11/04/26
Amylyx Pharmaceuticals to Participate in Upcoming November Investor ConferencesBusiness Wire • 11/03/26
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026Business Wire • 11/02/26
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBusiness Wire • 10/06/26
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumBusiness Wire • 09/23/26
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare ConferenceBusiness Wire • 09/08/26
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockBusiness Wire • 08/20/26
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study WinZacks Investment Research • 08/19/26
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockBusiness Wire • 08/18/26
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia TranscriptSeeking Alpha • 08/18/26
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 CatalystsSeeking Alpha • 08/18/26